Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04752813 · ClinicalTrials.gov registry record · Phase 2
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
A Phase 2 study of Glioblastoma and Glioblastoma Multiforme, sponsored by BPGbio.
- Active
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 11
- Study locations
NCT04752813: Active Phase 2 study of Glioblastoma and Glioblastoma Multiforme, sponsored by BPGbio.
NCT04752813 is a Phase 2 study of Glioblastoma and Glioblastoma Multiforme that is active but no longer recruiting, run by BPGbio. The registered enrollment target is 50 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (54% lower). The trial reports 11 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04752813, a Phase 2 study of Glioblastoma and Glioblastoma Multiforme, is active but no longer recruiting, sponsored by BPGbio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a single-arm, non-randomized, open-label Phase 2 therapeutic study that will assess the effects of adding BPM31510 onto a conventional treatment framework of RT and concurrent TMZ chemotherapy for subjects with newly diagnosed glioblastoma.
Primary Outcome
Progression free survival will be determined by measuring the proportion of subjects who have met RANO criteria for complete response, partial response , or stable disease at 6 mo and 12 mo following initiation of BPM31510.
Conditions Studied
Interventions
- RADIATION Radiation
- DRUG Temozolomide (TMZ)
- DRUG BPM31510
- OTHER Vitamin K1
Study Locations (11)
California
- Cedars-Sinai Medical Center - Los Angeles
- Stanford University Cancer Center - Palo Alto
- Sansum Clinic - Santa Barbara
Virginia
- Virginia Cancer Specialists - Fairfax
- Inova - Fairfax
- Virginia Oncology Associates - Norfolk
Texas
- Texas Oncology - Austin
- UT Health San Antonio Mays Cancer Center - San Antonio
Massachusetts
- Dana Farber Cancer Institute - Boston
New Jersey
- Valley Health - Ridgewood
New York
- Mount Sinai Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-08-22 |
| Est. Completion | 2030-08-26 |
| Phase | Phase 2 |
What the registry record for NCT04752813 still lists
NCT04752813 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (54% lower).
The record links to 2 conditions, with Glioblastoma appearing as the primary indexed condition, and to 4 interventions - of which Radiation is the first listed.
NCT04752813 lists 11 locations in 6 states (California, Virginia, Texas).
Frequently Asked Questions
What is clinical trial NCT04752813 about?
NCT04752813 is a clinical study titled "A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)". This is a single-arm, non-randomized, open-label Phase 2 therapeutic study that will assess the effects of adding BPM31510 onto a conventional treatment framework of RT and concurrent TMZ chemotherapy for subjects with newly diagnosed glioblastoma.
What is the current status of trial NCT04752813?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2022-08-22. Estimated completion is 2030-08-26.
What conditions does trial NCT04752813 study?
This clinical trial studies the following conditions: Glioblastoma, Glioblastoma Multiforme.
What interventions are being tested in trial NCT04752813?
The interventions under investigation include: Radiation (RADIATION), Temozolomide (TMZ) (DRUG), BPM31510 (DRUG), Vitamin K1 (OTHER).
Who is sponsoring clinical trial NCT04752813?
This trial is sponsored by BPGbio, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04752813 being conducted?
This trial has 11 study locations across California, Massachusetts, New Jersey, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04752813's enrollment target sits among peer trials
50 87th of 199 higher than 111 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI